ArticleInvestigational new drugs2016

Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors.

Manisha H Shah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.